Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

  • March 27, 2026

Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson & Johnson.

Leave A Comment

Fields (*) Mark are Required